<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Tonix Pharmaceuticals Holding Corp.

    Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...

    Tonix is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    TriplePulse, Inc.

    TriplePulse, Inc.

    TruBrain is a leading brand in high-performance cognitive nutrition with over $11....

    TruBrain is a leading brand in high-performance...

    Amount Raised:    $745,320.00
    Fundraising Status:    EC
    Filing Type:    CF
    ImmuCell Corporation

    ImmuCell Corporation

    ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically-proven...

    ImmuCell Corporation’s (Nasdaq: ICCC) purpose...

    Filing Type:    PU
    Quadrant Biosciences Inc

    Quadrant Biosciences Inc

    Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...

    Quadrant Biosciences is an epigenetic diagnosti...

    Filing Type:    RA
    Biogen Inc.

    Biogen Inc.

    At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...

    At Biogen, our mission is clear: we are pioneer...

    Filing Type:    PU
    Novan, Inc.

    Novan, Inc.

    Novan, Inc. is a clinical development-stage biotechnology company focused on lever...

    Novan, Inc. is a clinical development-stage bio...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...

    Iovance Biotherapeutics (formerly traded as Lio...

    Filing Type:    PU
    Corvus Pharmaceuticals, Inc.

    Corvus Pharmaceuticals, Inc.

    Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...

    Corvus Pharmaceuticals is a clinical science-dr...

    Filing Type:    PU
    Exicure, Inc.

    Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...

    Exicure, Inc. is a clinical stage biotechnology...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.